Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 215

    1.

    Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.

    Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M.

    Genome Biol. 2008 Oct 13;9(10):R150.

    PMID:
    18851746
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.

    Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Påhlman S, Guzhova I, Larsson LG.

    Mol Cancer Ther. 2007 Oct;6(10):2634-41.

    PMID:
    17938259
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.

    Vandesompele J, Edsjö A, De Preter K, Axelson H, Speleman F, Påhlman S.

    Oncogene. 2003 Jan 23;22(3):456-60.

    PMID:
    12545167
    [PubMed - indexed for MEDLINE]
    4.

    Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

    Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

    BMC Cancer. 2007 May 25;7:89. Review.

    PMID:
    17531100
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.

    Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, König R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, Khan J, Schwab M.

    Clin Cancer Res. 2007 Aug 15;13(16):4695-703. Epub 2007 Jul 25.

    PMID:
    17652624
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

    Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM.

    Cancer Res. 2003 Apr 1;63(7):1631-5.

    PMID:
    12670915
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.

    Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A, Maris JM, Hogarty MD.

    Oncogene. 2008 Feb 28;27(10):1478-88. Epub 2007 Aug 27.

    PMID:
    17724465
    [PubMed - indexed for MEDLINE]
    8.

    p53 is a direct transcriptional target of MYCN in neuroblastoma.

    Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

    Cancer Res. 2010 Feb 15;70(4):1377-88. Epub 2010 Feb 9.

    PMID:
    20145147
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.

    Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO, Ehemann V, Gillespie P, Schwab M, Westermann F.

    Cancer Res. 2010 May 1;70(9):3791-802. Epub 2010 Apr 27.

    PMID:
    20424123
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

    Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

    Cancer. 2001 Nov 15;92(10):2699-708.

    PMID:
    11745206
    [PubMed - indexed for MEDLINE]
    11.

    Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

    Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

    J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

    PMID:
    7674334
    [PubMed - indexed for MEDLINE]
    12.

    Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.

    Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL.

    Mol Carcinog. 2011 Jun;50(6):403-11. doi: 10.1002/mc.20722. Epub 2010 Dec 28.

    PMID:
    21557326
    [PubMed - indexed for MEDLINE]
    13.

    Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

    Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

    Int J Oncol. 2008 Nov;33(5):1081-9.

    PMID:
    18949372
    [PubMed - indexed for MEDLINE]
    14.

    Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.

    Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, Tang XX.

    Int J Oncol. 2011 Jan;38(1):105-12.

    PMID:
    21109931
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    The MYCN oncoprotein as a drug development target.

    Lu X, Pearson A, Lunec J.

    Cancer Lett. 2003 Jul 18;197(1-2):125-30. Review.

    PMID:
    12880971
    [PubMed - indexed for MEDLINE]
    16.

    MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.

    Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F, Vandesompele J.

    Oncogene. 2010 Mar 4;29(9):1394-404. Epub 2009 Nov 30.

    PMID:
    19946337
    [PubMed - indexed for MEDLINE]
    17.

    The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

    Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM.

    Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. Epub 2005 Jan 11.

    PMID:
    15644444
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.

    Gupta A, Williams BR, Hanash SM, Rawwas J.

    Cancer Res. 2006 Aug 15;66(16):8100-8.

    PMID:
    16912187
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.

    Manohar CF, Salwen HR, Brodeur GM, Cohn SL.

    Genes Chromosomes Cancer. 1995 Nov;14(3):196-203.

    PMID:
    8589036
    [PubMed - indexed for MEDLINE]
    20.

    Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.

    Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schäfer H, Christiansen H, Eilers M.

    Cancer Cell. 2002 Nov;2(5):377-86.

    PMID:
    12450793
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk